ATE190629T1 - Methoden zur behandlung von durch den tumor nekrose faktor ausgelösten krankheiten - Google Patents
Methoden zur behandlung von durch den tumor nekrose faktor ausgelösten krankheitenInfo
- Publication number
- ATE190629T1 ATE190629T1 AT92904429T AT92904429T ATE190629T1 AT E190629 T1 ATE190629 T1 AT E190629T1 AT 92904429 T AT92904429 T AT 92904429T AT 92904429 T AT92904429 T AT 92904429T AT E190629 T1 ATE190629 T1 AT E190629T1
- Authority
- AT
- Austria
- Prior art keywords
- tnf inhibitor
- methods
- 40kda
- tnf
- necrosis factor
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- 201000010099 disease Diseases 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 title 1
- 102000003390 tumor necrosis factor Human genes 0.000 title 1
- 229940046728 tumor necrosis factor alpha inhibitor Drugs 0.000 abstract 9
- 239000002451 tumor necrosis factor inhibitor Substances 0.000 abstract 9
- 108020004511 Recombinant DNA Proteins 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Physical Education & Sports Medicine (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Biophysics (AREA)
- Cardiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US64434591A | 1991-01-18 | 1991-01-18 | |
| PCT/US1992/000432 WO1992013095A1 (en) | 1991-01-18 | 1992-01-17 | Methods for treating tumor necrosis factor mediated diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE190629T1 true ATE190629T1 (de) | 2000-04-15 |
Family
ID=24584497
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT92904429T ATE190629T1 (de) | 1991-01-18 | 1992-01-17 | Methoden zur behandlung von durch den tumor nekrose faktor ausgelösten krankheiten |
Country Status (15)
| Country | Link |
|---|---|
| EP (1) | EP0567566B2 (de) |
| JP (2) | JP2864434B2 (de) |
| KR (1) | KR100234520B1 (de) |
| AT (1) | ATE190629T1 (de) |
| AU (2) | AU1235692A (de) |
| CA (1) | CA2100329C (de) |
| DE (1) | DE69230789T3 (de) |
| DK (1) | DK0567566T4 (de) |
| ES (1) | ES2145744T5 (de) |
| GE (1) | GEP20002142B (de) |
| GR (1) | GR3033327T3 (de) |
| NO (1) | NO316310B1 (de) |
| RU (1) | RU2166955C2 (de) |
| SG (1) | SG63617A1 (de) |
| WO (1) | WO1992013095A1 (de) |
Families Citing this family (82)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5512544A (en) * | 1987-09-13 | 1996-04-30 | Yeda Research And Development Co. Ltd. | Pharmaceutical compositions comprising an anticytokine |
| IL98078A0 (en) * | 1991-05-07 | 1992-06-21 | Yeda Res & Dev | Pharmaceutical compositions comprising an anticytokyne |
| US7264944B1 (en) | 1989-04-21 | 2007-09-04 | Amgen Inc. | TNF receptors, TNF binding proteins and DNAs coding for them |
| DE59010941D1 (de) * | 1989-04-21 | 2005-03-24 | Amgen Inc | TNF-Rezeptor, TNF bindende Proteine und dafür kodierende DNAs |
| US6221675B1 (en) | 1989-04-21 | 2001-04-24 | Amgen, Inc. | TNF receptors, TNF binding proteins and DNAs coding for them |
| IL95031A (en) | 1989-07-18 | 2007-03-08 | Amgen Inc | Method for the production of a human recombinant tumor necrosis factor inhibitor |
| US6143866A (en) * | 1989-07-18 | 2000-11-07 | Amgen, Inc. | Tumor necrosis factor (TNF) inhibitor and method for obtaining the same |
| EP0486526B2 (de) | 1989-08-07 | 2001-03-07 | Peptech Limited | Bindeligande für tumornekrosisfaktor |
| US20030225254A1 (en) | 1989-08-07 | 2003-12-04 | Rathjen Deborah Ann | Tumour necrosis factor binding ligands |
| DE59010908D1 (de) | 1989-09-12 | 2000-08-10 | Hoffmann La Roche | TNF-bindende Proteine |
| US6284471B1 (en) | 1991-03-18 | 2001-09-04 | New York University Medical Center | Anti-TNFa antibodies and assays employing anti-TNFa antibodies |
| US5698195A (en) * | 1991-03-18 | 1997-12-16 | New York University Medical Center | Methods of treating rheumatoid arthritis using chimeric anti-TNF antibodies |
| US5656272A (en) * | 1991-03-18 | 1997-08-12 | New York University Medical Center | Methods of treating TNF-α-mediated Crohn's disease using chimeric anti-TNF antibodies |
| US7192584B2 (en) | 1991-03-18 | 2007-03-20 | Centocor, Inc. | Methods of treating psoriasis with anti-TNF antibodies |
| US6277969B1 (en) | 1991-03-18 | 2001-08-21 | New York University | Anti-TNF antibodies and peptides of human tumor necrosis factor |
| EP0611302B1 (de) * | 1991-10-15 | 2000-03-29 | MULLARKEY, Michael F. | Rezeptoren zur Behandlung von Entzündungen vom verzögerten Typ |
| CA2118119C (en) * | 1992-04-30 | 2001-07-31 | Robert C. Thompson | Methods for treating interleukin-1 and tumor necrosis factor mediated diseases |
| NZ256293A (en) * | 1992-09-15 | 1997-06-24 | Immunex Corp | Method of treating tumour necrosis factor - mediated inflammation by use of tnf antagonist |
| US5457129A (en) * | 1993-05-17 | 1995-10-10 | Research Development Foundation | Inhibition of nitric oxide production by retinoic acid |
| US5446090A (en) * | 1993-11-12 | 1995-08-29 | Shearwater Polymers, Inc. | Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules |
| CA2139385C (en) * | 1994-02-04 | 2001-12-25 | Gottfried Alber | Products containing g-csf and tnf binding protein |
| US5629384A (en) * | 1994-05-17 | 1997-05-13 | Consiglio Nazionale Delle Ricerche | Polymers of N-acryloylmorpholine activated at one end and conjugates with bioactive materials and surfaces |
| US5824784A (en) | 1994-10-12 | 1998-10-20 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
| ES2171547T3 (es) * | 1995-07-14 | 2002-09-16 | Applied Research Systems | Receptor de tnf y hormona esteroidica dhea en terapia combinada. |
| US7012060B1 (en) | 1995-07-14 | 2006-03-14 | Applied Research Systems Ars Holding N.V. | TNF receptor and steroid hormone in a combined therapy |
| TW555765B (en) | 1996-07-09 | 2003-10-01 | Amgen Inc | Low molecular weight soluble tumor necrosis factor type-I and type-II proteins |
| ATE247974T1 (de) | 1996-12-06 | 2003-09-15 | Amgen Inc | Kombinationtherapie mit einem tnf-bindendem protein zür behandlung von durch tnf verursachten erkrangungen |
| CA2273852C (en) | 1996-12-06 | 2009-09-29 | Amgen Inc. | Combination therapy using an il-1 inhibitor for treating il-1 mediated diseases |
| CA2310575A1 (en) * | 1997-11-07 | 1999-05-20 | Uab Research Foundation | Method for the augmentation of gene expression |
| EP1123314B1 (de) * | 1998-10-20 | 2004-02-18 | Vlaams Interuniversitair Instituut voor Biotechnologie vzw. | Verwendung eines zytokine-produzierenden lactococcus stammes zur behandlung von kolitis |
| US6660843B1 (en) | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
| US20040220103A1 (en) | 1999-04-19 | 2004-11-04 | Immunex Corporation | Soluble tumor necrosis factor receptor treatment of medical disorders |
| US6808902B1 (en) | 1999-11-12 | 2004-10-26 | Amgen Inc. | Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules |
| WO2001064889A2 (en) | 2000-03-02 | 2001-09-07 | Xencor | Tnf-alpha variants for the treatment of tnf-alpha related disorders |
| UA81743C2 (uk) | 2000-08-07 | 2008-02-11 | Центокор, Инк. | МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ |
| TR201809678T4 (tr) | 2001-06-26 | 2018-07-23 | Amgen Fremont Inc | Opgl ye karşi antikorlar. |
| TWI327597B (en) | 2001-08-01 | 2010-07-21 | Centocor Inc | Anti-tnf antibodies, compositions, methods and uses |
| US7585840B2 (en) | 2002-04-10 | 2009-09-08 | Merck Serono S.A. | Use of osteoprotegerin for the treatment and/or prevention of fibrotic disease |
| AU2003240754B2 (en) | 2002-04-10 | 2009-02-26 | Merck Serono Sa | Use of osteoprotegerin for the prevention and/or treatment of fibrosis/sclerosis |
| US9028822B2 (en) | 2002-06-28 | 2015-05-12 | Domantis Limited | Antagonists against TNFR1 and methods of use therefor |
| BR0315155A (pt) | 2002-10-08 | 2005-08-16 | Ares Trading Sa | Uso de citocina capaz de ligar il-18bp e de inibir a atividade de uma segunda citocina |
| US7892563B2 (en) | 2003-05-20 | 2011-02-22 | Wyeth Holdings Corporation | Methods for treatment of severe acute respiratory syndrome (SARS) |
| US7482376B2 (en) | 2003-07-03 | 2009-01-27 | 3-Dimensional Pharmaceuticals, Inc. | Conjugated complement cascade inhibitors |
| IL161673A0 (en) | 2004-04-29 | 2004-09-27 | Applied Research Systems | Compositions and methods for therapy of chemotherapy-induced neuropathy |
| IL161672A0 (en) | 2004-04-29 | 2004-09-27 | Yeda Res & Dev | Compositions and methods for therapy of chemotherapy-induced neuropathy |
| WO2006114387A2 (en) | 2005-04-26 | 2006-11-02 | Laboratoires Serono S.A. | Insp163 polypeptides for the treatment or prevention of cancer and arthritis |
| CA2609060C (en) | 2005-06-03 | 2014-07-15 | Urs Weber | Production of recombinant il-18 binding protein |
| PT1891088E (pt) | 2005-06-10 | 2011-12-19 | Ares Trading Sa | Processo para a purificação da proteína de ligação il-18 |
| BRPI0613042A2 (pt) | 2005-07-15 | 2010-12-14 | Serono Lab | inibidores de jnk para o tratamento de endometriose |
| KR20080044836A (ko) | 2005-07-15 | 2008-05-21 | 라보라뚜와르 세로노 에스. 에이. | 자궁내막증 치료용 jnk 억제제 |
| US20080219952A1 (en) | 2005-08-26 | 2008-09-11 | Ares Trading S.A. | Process For the Preparation of Glycosylated Interferon Beta |
| EP1933860A2 (de) | 2005-09-01 | 2008-06-25 | Ares Trading S.A. | Behandlung von optikusneuritis |
| WO2007051785A2 (en) | 2005-10-31 | 2007-05-10 | Laboratoire Serono S.A. | Use of sdf-1 for the treatment and/or prevention of neurological diseases |
| US8795668B2 (en) * | 2005-12-23 | 2014-08-05 | The Regents Of The University Of Michigan | Methods for treating pulmonary fibrosis |
| IL173104A0 (en) | 2006-01-12 | 2006-06-11 | Yeda Res & Dev | Siva and ubiquintination |
| MX2008014971A (es) | 2006-05-24 | 2008-12-05 | Serono Lab | Regimen de cladribine para tratar esclerosis multiple. |
| US7767206B2 (en) | 2006-10-02 | 2010-08-03 | Amgen Inc. | Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto |
| EP2121931B1 (de) | 2007-01-26 | 2011-05-11 | Merck Serono S.A. | Aufreinigung von fc-tact-fusionsproteinen unter verwendung der ölkörper-technik |
| EP2203465A1 (de) | 2007-10-22 | 2010-07-07 | Merck Serono S.A. | Verfahren zu reinigung eines fc enthaltenden proteins |
| US8415291B2 (en) | 2008-10-31 | 2013-04-09 | Centocor Ortho Biotech Inc. | Anti-TNF alpha fibronectin type III domain based scaffold compositions, methods and uses |
| EP2899212B1 (de) | 2009-03-30 | 2017-07-19 | Edimer Biotech S.a. | Herstellung von isolierten monoklonalen Agonist-Anti-EDAR-Antikörpern |
| TW201117824A (en) | 2009-10-12 | 2011-06-01 | Amgen Inc | Use of IL-17 receptor a antigen binding proteins |
| SI2523688T1 (en) | 2010-01-15 | 2018-03-30 | Kirin-Amgen, Inc. | Formulation of antibodies and therapeutic regimes |
| WO2011145085A2 (en) | 2010-05-21 | 2011-11-24 | Procognia (Israel) Ltd | Novel antibodies and methods of use for the treatment and diagnosis of cancer |
| CN103347520A (zh) | 2010-10-13 | 2013-10-09 | 波士顿大学管理委员会 | 用作癌症化学治疗的晚期sv40因子(lsf)的抑制剂 |
| US20140234330A1 (en) | 2011-07-22 | 2014-08-21 | Amgen Inc. | Il-17 receptor a is required for il-17c biology |
| EP2825173B1 (de) | 2012-03-16 | 2018-10-10 | Children's Medical Center Corporation | Calmodulin-hemmer zur behandlung von ribosomalen erkrankungen und ribosomapathien |
| US9751942B2 (en) | 2012-03-29 | 2017-09-05 | Chugai Seiyaku Kabushiki Kaisha | Anti-LAMP5 antibody and utilization thereof |
| WO2015032932A1 (en) | 2013-09-05 | 2015-03-12 | Ab2 Bio Sa | Il-18 binding protein (il-18bp) in inflammatory diseases |
| KR102530900B1 (ko) | 2014-03-31 | 2023-05-12 | 암젠 케이-에이, 인크. | 손발톱 및 두피 건선의 치료 방법 |
| CN107660150B (zh) | 2015-03-05 | 2023-10-24 | Ab2生物股份有限公司 | Il-18结合蛋白(il-18bp)和抗体在炎性疾病中 |
| US10465003B2 (en) | 2016-02-05 | 2019-11-05 | Janssen Biotech, Inc. | Anti-TNF antibodies, compositions, methods and use for the treatment or prevention of type 1 diabetes |
| DK3484474T3 (da) | 2016-07-13 | 2024-06-24 | Childrens Medical Ct Corp | Phenothiazinforbindelser til behandlingen af ribosomale lidelser og ribosomopatier |
| CN110234351A (zh) | 2017-01-30 | 2019-09-13 | 詹森生物科技公司 | 用于治疗活动性银屑病关节炎的抗tnf抗体、组合物和方法 |
| KR20240038148A (ko) | 2017-02-07 | 2024-03-22 | 얀센 바이오테크 인코포레이티드 | 활성 강직성 척추염의 치료를 위한 항-tnf 항체, 조성물, 및 방법 |
| AR113906A1 (es) | 2017-11-24 | 2020-06-24 | Merck Patent Ges Mit Beschraenkter Haftung | Régimen con cladribina para tratar formas progresivas de la esclerosis múltiple |
| EP3972690A4 (de) | 2019-05-23 | 2023-07-05 | Janssen Biotech, Inc. | Verfahren zur behandlung einer entzündlichen darmerkrankung mit einer kombinationstherapie von antikörpern gegen il-23 und tnf-alpha |
| EP4146174A1 (de) | 2020-05-06 | 2023-03-15 | AB2 Bio SA | Il-18-bindendes protein (il-18bp) bei atemwegserkrankungen |
| CA3183927A1 (en) | 2020-05-21 | 2021-11-25 | Janssen Biotech, Inc. | Method of treating inflammatory bowel disease with a combination therapy of antibodies to il-23 and tnf alpha |
| EP3943097A1 (de) | 2020-07-24 | 2022-01-26 | AB2 Bio SA | Car-t-zelltherapie |
| IL301246A (en) | 2020-09-10 | 2023-05-01 | Merck Patent Gmbh | Treatment regimen with cladribine |
| EP4486367A1 (de) | 2022-03-04 | 2025-01-08 | AB2 Bio SA | Il-18-bindendes protein (il-18bp) zur behandlung von vexas |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1283046C (en) * | 1986-05-29 | 1991-04-16 | Nandini Katre | Tumor necrosis factor formulation |
| IL83878A (en) * | 1987-09-13 | 1995-07-31 | Yeda Res & Dev | Soluble protein corresponding to tnf inhibitory protein its preparation and pharmaceutical compositions containing it |
| GB8807803D0 (en) * | 1988-03-31 | 1988-05-05 | Glaxo Group Ltd | Biochemical product |
| SU1671310A1 (ru) * | 1989-01-30 | 1991-08-23 | Всесоюзный Научно-Исследовательский Институт Экспериментальной Ветеринарии Им.Я.Р.Коваленко | Способ профилактики вирусных заболеваний птиц |
| DE59010941D1 (de) * | 1989-04-21 | 2005-03-24 | Amgen Inc | TNF-Rezeptor, TNF bindende Proteine und dafür kodierende DNAs |
| DE3922089A1 (de) * | 1989-05-09 | 1990-12-13 | Basf Ag | Neue proteine und ihre herstellung |
| IL95031A (en) * | 1989-07-18 | 2007-03-08 | Amgen Inc | Method for the production of a human recombinant tumor necrosis factor inhibitor |
| AU1674292A (en) * | 1991-03-15 | 1992-10-21 | Synergen, Inc. | Pegylation of polypeptides |
-
1992
- 1992-01-17 GE GEAP19922664A patent/GEP20002142B/en unknown
- 1992-01-17 DE DE69230789T patent/DE69230789T3/de not_active Expired - Lifetime
- 1992-01-17 CA CA002100329A patent/CA2100329C/en not_active Expired - Lifetime
- 1992-01-17 SG SG1996007283A patent/SG63617A1/en unknown
- 1992-01-17 ES ES92904429T patent/ES2145744T5/es not_active Expired - Lifetime
- 1992-01-17 AU AU12356/92A patent/AU1235692A/en not_active Abandoned
- 1992-01-17 DK DK92904429T patent/DK0567566T4/da active
- 1992-01-17 KR KR1019930702129A patent/KR100234520B1/ko not_active Expired - Lifetime
- 1992-01-17 WO PCT/US1992/000432 patent/WO1992013095A1/en not_active Ceased
- 1992-01-17 AT AT92904429T patent/ATE190629T1/de not_active IP Right Cessation
- 1992-01-17 EP EP92904429A patent/EP0567566B2/de not_active Expired - Lifetime
- 1992-01-17 RU RU93051522/14A patent/RU2166955C2/ru active
- 1992-01-17 JP JP4504597A patent/JP2864434B2/ja not_active Expired - Lifetime
-
1993
- 1993-07-19 NO NO19932610A patent/NO316310B1/no not_active IP Right Cessation
-
1996
- 1996-02-02 AU AU42288/96A patent/AU702466B2/en not_active Withdrawn - After Issue
-
1998
- 1998-09-10 JP JP29598898A patent/JP3210629B2/ja not_active Expired - Lifetime
-
2000
- 2000-04-26 GR GR20000401011T patent/GR3033327T3/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP0567566B1 (de) | 2000-03-15 |
| CA2100329A1 (en) | 1992-07-19 |
| EP0567566A1 (de) | 1993-11-03 |
| NO316310B1 (no) | 2004-01-12 |
| DE69230789T3 (de) | 2007-10-31 |
| ES2145744T3 (es) | 2000-07-16 |
| SG63617A1 (en) | 1999-03-30 |
| NO932610L (no) | 1993-09-09 |
| JPH06506446A (ja) | 1994-07-21 |
| DE69230789D1 (de) | 2000-04-20 |
| WO1992013095A1 (en) | 1992-08-06 |
| GR3033327T3 (en) | 2000-09-29 |
| RU2166955C2 (ru) | 2001-05-20 |
| CA2100329C (en) | 2009-09-29 |
| AU702466B2 (en) | 1999-02-25 |
| DK0567566T4 (da) | 2007-10-22 |
| DE69230789T2 (de) | 2000-08-31 |
| JPH11199505A (ja) | 1999-07-27 |
| ES2145744T5 (es) | 2008-02-01 |
| JP2864434B2 (ja) | 1999-03-03 |
| NO932610D0 (no) | 1993-07-19 |
| DK0567566T3 (da) | 2000-07-31 |
| AU1235692A (en) | 1992-08-27 |
| EP0567566B2 (de) | 2007-07-04 |
| GEP20002142B (en) | 2000-06-25 |
| KR100234520B1 (ko) | 1999-12-15 |
| EP0567566A4 (en) | 1994-10-05 |
| AU4228896A (en) | 1996-04-18 |
| JP3210629B2 (ja) | 2001-09-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69230789D1 (de) | Methoden zur behandlung von durch den tumor nekrose faktor ausgelösten krankheiten | |
| RU93051522A (ru) | Способ лечения и профилактики заболеваний, обусловленных повышением уровня фактора, вызывающего некроз опухолевых клеток | |
| DE69327582D1 (de) | Methoden zur Behandlung von Interleukin- 1 und - Tumor - Nekrose - Faktor - verursachten Krankheiten | |
| DE69724451D1 (de) | Kombinationtherapie mit einem tnf-bindendem protein zür behandlung von durch tnf verursachten erkrangungen | |
| ATE298800T1 (de) | Verfahren und desoxyribonukleinsäure zur herstellung von gewebefaktor-protein | |
| ATE298566T1 (de) | Proteintyrosine-kinaseinhibitoren zur behandlung der osteoarthritis | |
| DE69616375D1 (de) | Nicht-allosterische GABA A Agonisten zur Behandlung von Schlafstörungen | |
| DE69835823D1 (de) | Verfahren zur behandlung von patienten die unter multipler sklerose leiden mit konsensus-interferon | |
| ATE79763T1 (de) | Verwendung von mindestens ein cytokin zur herstellung eines arzneimittels zur systemischen behandlung von praeneoplastischen laesionen. | |
| DE68905203D1 (de) | Verwendung von igf i zur herstellung eines praeparates fuer die behandlung von nierenkrankheiten. | |
| DE69535264D1 (de) | Verfahren zur behandlung von diabetes mittels kgf | |
| FI840748A0 (fi) | Kinolonkarbonsyror, foerfarande foer deras framstaellning och dessa innehaollande antibakteriella aemnen | |
| DE69636654D1 (de) | Verfahren zur verabreichung von igf-1 | |
| DE60115433D1 (de) | Verfahren zur behandlung von chronischen geschwüren | |
| DE69637440D1 (de) | Hapten modifizierter tumorzellextrakt und verfahren zur behandlung von krebs | |
| ATE180277T1 (de) | Zur behandlung von tumoren und hiv-infektionen nützliches pflanzliches protein | |
| ATE194076T1 (de) | Verwendung von n,s-diacetylcystein-ethylester (dacee) zur herstellung eines medikaments zur behandlung viraler erkrankungen | |
| DE69433996D1 (de) | Verwendung pharmazeutischer zusammensetzungen zur behandlung von neurodegenerativen krankheiten | |
| IT8822122A0 (it) | Procedimento per la preparazione di acidi fosfinici utilizzati nella preparazione di inibitori di ace ed intermedi cosi' prodotti. | |
| EP0324447A3 (de) | Mittel und Verfahren zur Herstellung eines rekombinanten, menschlichen Interleukin-1 alpha-Polypeptides | |
| DE69307702D1 (de) | Verwendung von (e) - 2 - (p -fluorophenethyl)- 3 - fluoroallylamine zur behandlung der alzheimerschen krankheit | |
| DK0580782T3 (da) | Anti-HIV-protein, TAP 29, fra Trichosanthes, DNA, som koder derfor, og terapeutiske anvendelser deraf | |
| ATE192039T1 (de) | Verfahren zur herstellung von reinem nizatidin | |
| DE69732851D1 (de) | Verwendung von dextrinsulfat zur behandlung von sehr vasculären tumoren | |
| HASHIMOTO | Stereological studies of vascularization phenomena 9. The healing process of bone defect following experimental mandibular osteotomy in macacus cynomolgos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification | ||
| UEP | Publication of translation of european patent specification |
Ref document number: 0567566 Country of ref document: EP |
|
| EELA | Cancelled due to lapse of time |